Mycobacterium tuberculosis: Difference between revisions

From IDWiki
Mycobacterium tuberculosis
(→: changed drugs to a table)
(→)
 
(32 intermediate revisions by the same user not shown)
Line 1: Line 1:
−
* ''Mycobacterium tuberculosis'' causes '''tuberculosis'''
  
−
* Most commonly '''pulmonary TB''' but extrapulmonary tuberculosis is possible (including adenitis, gastrointestinal TB, pericarditis, meningitis)
  
−
* Standard treatment for susceptible TB is '''RIPE x2mo then RI x4mo'''
  
−  
 
== Background ==
  
== Background ==
  +
*''Mycobacterium tuberculosis'' causes '''tuberculosis'''
−
=== Microbiology ===
  
  +
*Most commonly '''pulmonary TB''' but extrapulmonary tuberculosis is possible (including adenitis, gastrointestinal TB, pericarditis, meningitis)
−
* Fastidious, aerobic [[Has Gram stain::acid-fast]] [[Has shape::bacillus]]
  
  +
*Standard treatment for susceptible TB is '''RIPE x2mo then RI x4mo'''
−
* Cell wall has high lipid content
  
  +
−
* Generation time is very long (15 to 20 hours)
  
  +
==Microbiology==
  +
*Fastidious, aerobic [[Stain::acid-fast]] [[Shape::bacillus]]
  +
*Cell wall has high lipid content
  +
*Generation time is very long (15 to 20 hours)
 
*''M. tuberculosis'' is a complex that comprises seven species:
  
*''M. tuberculosis'' is a complex that comprises seven species:
−
** ''M. tuberculosis'' sensu stricto: most common causative organism worldwide
 +
**''M. tuberculosis'' sensu stricto: most common causative organism worldwide
−
** ''M. africanum'': 50% of cases in West africa
 +
**''M. africanum'': 50% of cases in West africa
−
** ''M. canetti'': rare cause in Eastern African
 +
**''M. canetti'': rare cause in Eastern African
−
** ''M. bovis'': disease in cattle but can infect humans
 +
**''M. bovis'': disease in cattle but can infect humans
−
** ''M. caprae'': disease in cattle
 +
**''M. caprae'': disease in cattle
−
** ''M. microti'': disease in rodents
 +
**''M. microti'': disease in rodents
−
** ''M. pinnipdeii'': disease in seals, with rare human infection
 +
**''M. pinnipdeii'': disease in seals, with rare human infection
   
−
=== Epidemiology ===
 +
===Epidemiology===
−
* Typically spread via airborne route
  
−
** Droplets are expelled during coughing, sneezing, or talking, and are suspended in the air
  
−
** They can remain for up to 30 minutes
  
−
** Killed by ultraviolet light
  
−
** Not transmitted via fomites
  
−
* About a third of the world is infected, mostly as latent tuberculosis
  
−
** This progresses to active tuberculosis at about 3 or 4% in the first year and 5% over the rest of their life
  
−
* Reinfection accounts for ~40% of active tuberculosis in endemic countries
  
−
* Highest rates in sub-Saharan Africa and south/southeast Asia
  
   
  +
*Typically spread via airborne route
−
=== Risk Factors ===
  
  +
**Droplets are expelled during coughing, sneezing, or talking, and are suspended in the air
−
* Source factors, such as sputum smear positivity, cough, cavitations
  
  +
**They can remain for up to 30 minutes
−
* Exposure duration, closeness of contact
  
  +
**Killed by ultraviolet light
−
* Factors in the exposed person, such as immune compromise, HIV status
  
  +
**Not transmitted via fomites
  +
*About a third of the world is infected, mostly as latent tuberculosis
  +
**This progresses to active tuberculosis at about 3 or 4% in the first year and 5% over the rest of their life
  +
*Reinfection accounts for ~40% of active tuberculosis in endemic countries
  +
*Highest rates in sub-Saharan Africa and south/southeast Asia
   
  +
===Risk Factors===
−
== Clinical Presentation ==
  
−
=== Classification ===
  
−
* Primary vs. reactivation vs. reinfection
  
−
* Latent vs. active
  
   
  +
*Source factors, such as sputum smear positivity, cough, cavitations
−
=== Primary tuberculosis ===
  
  +
*Exposure duration, closeness of contact
−
* Primary tuberculosis is usually asymptomatic
  
  +
*Factors in the exposed person, such as immune compromise, HIV status
−
* Possible presentations include mild URTI with cough and/or fever
  
−
* May be seen on CXR as infiltrate in mid-lung zones with hilar adenopathy
  
−
* Ghon complex, especially in children
  
−
* May progress in children and the immunocompromised patients
  
−
* Immunological phenomena
  
−
** Erythema nodosum
  
−
** Phlyctenular conjunctivitis
  
−
** Erythema induratum
  
   
  +
==Clinical Manifestations==
−
=== Pulmonary tuberculosis ===
  
  +
===Classification===
−
* Most common presentation of active tuberculosis
  
−
* Refer to separate article on [[pulmonary tuberculosis]]
  
   
  +
*Primary vs. reactivation vs. reinfection
−
=== Extra-pulmonary tuberculosis ===
  
  +
*Latent vs. active
−
* Pleural tuberculosis is most common extrapulmonary site
  
−
* [[Scrofula]] (cervical lymph node infection) next-most common
  
−
* [[Tuberculous meningitis]]
  
−
* [[Tuberculous pericarditis]]
  
−
* Renal tuberculosis
  
−
* Abdominal tuberculosis
  
−
* Gastrointestinal tuberculosis
  
   
−
=== Latent tuberculosis ===
 +
===Primary Tuberculosis===
−
* Refers to chronic latent infection contained within granulomas that may reactivate in the future
  
−
* Refer to [[Latent tuberculosis infection]]
  
   
  +
*Primary tuberculosis is usually asymptomatic
−
== Investigations ==
  
  +
*Possible presentations include mild URTI with cough and/or fever
−
* Radiography: chest x-ray with or without CT chest
  
  +
*May be seen on CXR as infiltrate in mid-lung zones with hilar adenopathy
−
** Primary TB: consolidation, lymphadenopathy, pleural effusion, Ghon complex
  
  +
*Ghon complex, especially in children
−
** Reactivation TB: patchy upper-lobe consolidation, cavitation, fibrosis, pleural disease
  
  +
*May progress in children and the immunocompromised patients
−
** Miliary TB: uniform 1-3 mm diameter diffuse nodules
  
  +
*Immunological phenomena
  +
**Erythema nodosum
  +
**Phlyctenular conjunctivitis
  +
**Erythema induratum
   
  +
===Pulmonary Tuberculosis===
−
== Diagnosis ==
  
−
* Latent tuberculosis testing
  
−
** Tuberculin skin test (TST)
  
−
** Interferon-gamma release assay (IGRA)
  
−
* Serology or immunologic testing
  
−
** Urine lipoarabinomannan antigen
  
−
* Microbiology
  
−
** Samples can include routine or induced sputum (x3) or bronchoscopy, or tissue sample
  
−
** Spontaneous sputum should include at least one morning sputum, ideally, but can be done all in a row at least one hour apart if needed
  
−
** Acid-fast bacillus culture of sputum x3 is about 70% sensitive, and PCR (ANTB) x1 is about 75% sensitive
  
−
* Molecular testing
  
−
** PCR, including GeneXpert
  
   
  +
*Most common presentation of active tuberculosis
−
== Management ==
  
−
* See also [[Pulmonary tuberculosis#Management|management of pulmonary tuberculosis]]
 +
*Refer to separate article on [[pulmonary tuberculosis]]
   
  +
===Extra-Pulmonary Tuberculosis===
  +
  +
*Pleural tuberculosis is most common extrapulmonary site
  +
*[[Scrofula]] (cervical lymph node infection) next-most common
  +
*[[Tuberculous meningitis]]
  +
*[[Tuberculous pericarditis]]
  +
*Renal tuberculosis
  +
*Abdominal tuberculosis
  +
*Gastrointestinal tuberculosis
  +
*[[Cutaneous tuberculosis]]
  +
  +
===Latent Tuberculosis===
  +
  +
*Refers to chronic latent infection contained within granulomas that may reactivate in the future
  +
*Refer to [[Latent tuberculosis infection]]
  +
  +
===Other===
  +
  +
*[[Neonatal tuberculosis]]
  +
  +
==Investigations==
  +
  +
*Radiography: chest x-ray with or without CT chest
  +
**Primary TB: consolidation, lymphadenopathy, pleural effusion, Ghon complex
  +
**Reactivation TB: patchy upper-lobe consolidation, cavitation, fibrosis, pleural disease
  +
**Miliary TB: uniform 1-3 mm diameter diffuse nodules
  +
  +
==Diagnosis==
  +
  +
*[[Latent tuberculosis infection#Diagnosis|Latent tuberculosis testing]]
  +
**Tuberculin skin test (TST)
  +
**Interferon-gamma release assay (IGRA)
  +
*Serology or immunologic testing
  +
**Urine lipoarabinomannan antigen
  +
*Microbiology
  +
**Samples can include routine or induced sputum (x3 q8h including 1 early AM) or bronchoscopy, or tissue sample
  +
**Spontaneous sputum should include at least one morning sputum, ideally, but can be done all in a row at least one hour apart if needed
  +
**Acid-fast bacillus culture of sputum x3 is about 70% sensitive, and PCR (ANTB) x1 is about 75% sensitive
  +
*Molecular testing
  +
**PCR, including GeneXpert
  +
  +
==Management==
  +
  +
* Requires at least 2 effective drugs at all times, including at least 3 effective drugs during intensive phase
  +
** Consider rapid rifampin resistance testing (PCR) in all patients
  +
* Most patients are started on RIPE
  +
**In cases of increased risk for [[MDR-TB]], still use RIPE while awaiting rapid rifampin testing
  +
**Typical duration is intensive therapy for 2 months (with at least 3 drugs), then narrowed to at least 2 drugs for the remainder of treatment
  +
**Rifampin is the most effective agent, and any regimen that excludes rifampin must be extended to 12-18 months
  +
* See also:
  +
** [[Pulmonary tuberculosis#Management|Management of pulmonary tuberculosis]]
  +
** [[Tuberculous meningitis#Management|Management of tuberculous meningitis]]
  +
** [[Drug-resistant tuberculosis#Management|Management of drug-resistant tuberculosis]]
  +
  +
===Antibiotics===
 
{| class="wikitable"
  
{| class="wikitable"
−
! Drug !! Dose !! Side effects
 +
!Drug!!Dose!!Side effects
 
|-
  
|-
−
! colspan="3" | First-line medications
 +
! colspan="3" |First-Line Medications
−
|-
  
−
| [[Is treated by::Isoniazid]]
  
−
| 5 mg/kg daily, max 300 mg daily, with pyridoxine 25 mg po daily
  
−
| Rash, hepatitis, neuropathy, CNS toxicity, anemia
  
 
|-
 
|-
−
| [[Is treated by::Rifampin]]
 +
|[[Is treated by::Rifampin]]
−
| 10 mg/kg daily
 +
|10 mg/kg daily, no max
−
| Drug interactions, rash, hepatitis, flu-like illness, neutropenia, thrombocytopenia
 +
|Drug interactions, rash, hepatitis, flu-like illness, neutropenia, thrombocytopenia
 
|-
  
|-
−
| [[Is treated by::Pyrazinamide]]
 +
|[[Is treated by::Isoniazid]]
−
| 25 mg/kg daily, max 2 g daily
 +
|5 mg/kg daily, max 300 mg daily, with pyridoxine 25 mg po daily
  +
|Rash, hepatitis, neuropathy, CNS toxicity, anemia
−
| Hepatitis, rash, arthralgia, gout
  
 
|-
  
|-
−
| [[Is treated by::Ethambutol]]
 +
|[[Is treated by::Pyrazinamide]]
−
| 20 mg/kg daily, max 1.2 g daily
 +
|25 mg/kg daily, max 2 g daily
  +
|Hepatitis, rash, arthralgia, gout
−
| Optic/retrobulbar neuritis, rash
  
 
|-
  
|-
  +
|[[Is treated by::Ethambutol]]
−
! colspan="3" | Second-line medications
  
  +
|15 mg/kg daily, max 1.6 g daily
  +
|Optic/retrobulbar neuritis, rash
 
|-
  
|-
  +
! colspan="3" |Second-Line Medications
−
| [[Is treated by::Streptomycin]]
  
−
| 15 mg/kg daily, max 1 g
  
−
| rowspan="2" | Auditory and vestibular toxicity, renal toxocity, avoid in pregnancy
  
 
|-
  
|-
−
| [[Is treated by::Amikacin]], [[Is treated by::kanamycin]], or [[Is treated by::capreomycin]]
 +
|[[Is treated by::Streptomycin]]
−
| 15 mg/kg daily, man 1 g
 +
|15 mg/kg daily, max 1 g
  +
| rowspan="2" |Auditory and vestibular toxicity, renal toxocity, avoid in pregnancy
 
|-
  
|-
−
| [[Is treated by::Ethionamide]]
 +
|[[Is treated by::Amikacin]], [[Is treated by::kanamycin]], or [[Is treated by::capreomycin]]
−
| 250 mg BID to TID, max 1 g
 +
|15 mg/kg daily, man 1 g
−
| GI disturbance, hepatotoxicity, endocrine effects, neurotoxicity, avoid in pregnancy
  
 
|-
  
|-
−
| [[Is treated by::Para-amino salicylic acid]]
 +
|[[Is treated by::Ethionamide]]
−
| 4 g BID or TID, max 10 g
 +
|250 mg BID to TID, max 1 g
−
| GI disturbance, hepatic dysfunction, hypothyroidism, avoid in aspirin allergy
 +
|GI disturbance, hepatotoxicity, endocrine effects, neurotoxicity, avoid in pregnancy
 
|-
  
|-
−
| [[Is treated by::Cycloserine]]
 +
|[[Is treated by::Para-amino salicylic acid]]
−
| 250 mg BID to TID, max 1 g
 +
|4 g BID or TID, max 10 g
  +
|GI disturbance, hepatic dysfunction, hypothyroidism, avoid in aspirin allergy
−
| Avoid in epilepsy, psychiatric illness, and alcoholism
  
 
|-
  
|-
−
| [[Is treated by::Levofloxacin]]
 +
|[[Is treated by::Cycloserine]]
−
| 500 to 1000 mg po daily
 +
|250 mg BID to TID, max 1 g
  +
|Avoid in epilepsy, psychiatric illness, and alcoholism
−
| rowspan="2" | GI disturbance, headache, anxiety, tremor, long QT, avoid in pregnancy and children
  
 
|-
  
|-
−
| [[Is treated by::Moxifloxacin]]
 +
|[[Is treated by::Levofloxacin]]
−
| 400 to 600 mg daily
 +
|500 to 1000 mg po daily
  +
| rowspan="2" |GI disturbance, headache, anxiety, tremor, long QT, avoid in pregnancy and children
 
|-
  
|-
−
| [[Is treated by::Rifabutin]]
 +
|[[Is treated by::Moxifloxacin]]
−
| 300 mg daily
 +
|400 to 600 mg daily
−
| Hepatotoxicity, uveitis, thrombocytopenia, neutropenia, drug interactions
  
 
|-
  
|-
−
| [[Is treated by::Clofazimine]]
 +
|[[Is treated by::Rifabutin]]
−
| 100 to 300 mg daily
 +
|300 mg daily
  +
|Hepatotoxicity, uveitis, thrombocytopenia, neutropenia, drug interactions
−
| Rash, conjunctiva, cornea, body fluid discolouration, GI intolerance, photosensitivity
  
 
|-
  
|-
−
| [[Is treated by::Linezolid]]
 +
|[[Is treated by::Clofazimine]]
−
| 600 mg po daily
 +
|100 to 300 mg daily
  +
|Skin discolouration, conjunctiva, cornea, body fluid discolouration, GI intolerance, photosensitivity
−
|
 
  +
|-
  +
! colspan="3" |Third-Line Medications
  +
|-
  +
|[[Is treated by::Linezolid]]
  +
|600 mg po daily
  +
|
  +
|-
  +
|[[Bedaquiline]]
  +
|400 mg po daily for 2 weeks followed by 200 mg thrice weekly
  +
|Arthralgias, dizziness, headache, hyperuriemia, insomnia, myalgia, nausea, prolonged ECG QT interval, pruritus, and vomiting
  +
|-
  +
|[[Pretomanid]]
  +
|
  +
|
  +
|-
  +
|[[Delamanid]]
  +
|
  +
|
  +
|-
  +
! colspan="3" |Adjunctive Therapies
  +
|-
  +
|Corticosteroids for patients with [[tuberculous meningitis]] or [[tuberculous pericarditis]]
  +
|[[Prednisone]] 40 to 80 mg po daily for 6 to 12 weeks
  +
|
 
|}
  
|}
   
  +
==== Doses by Weight ====
−
* Add steroids for patients with [[tuberculous meningitis]] or [[tuberculous pericarditis]]
  
  +
{| class="wikitable"
−
** e.g. prednisone 40 to 80 mg po daily for 6 to 12 weeks
  
  +
! rowspan="2" |Drug
  +
! rowspan="2" |Dose
  +
! rowspan="2" |Tabs
  +
! colspan="5" |Weight (kg)
  +
|-
  +
!30-35
  +
!36-45
  +
!46-55
  +
!56-70
  +
!>70
  +
|-
  +
! colspan="8" |First-Line Medications
  +
|-
  +
|[[rifampin]]
  +
|10 mg/kg
  +
|150 & 300 mg
  +
|300 mg
  +
| colspan="2" |450 mg
  +
| colspan="2" |600 mg
  +
|-
  +
|[[isoniazid]]
  +
|5 mg/kg
  +
|100 & 300 mg
  +
|150 mg
  +
|200 mg
  +
| colspan="3" |300 mg
  +
|-
  +
|[[pyrazinamide]]
  +
|25 mg/kg
  +
|500 mg
  +
|750 mg
  +
|1000 mg
  +
|1250 mg
  +
|1500 mg
  +
|1750-2000 mg
  +
|-
  +
|[[ethambutol]]
  +
|15 mg/kg
  +
|100 & 400 mg
  +
|600 mg
  +
|800 mg
  +
|1000 mg
  +
| colspan="2" |1200 mg
  +
|-
  +
! colspan="8" |Alternative Medications
  +
|-
  +
|[[rifabutin]]
  +
|
  +
|
  +
| colspan="5" |300 mg
  +
|-
  +
|[[levofloxacin]]
  +
|
  +
|
  +
| colspan="2" |750 mg
  +
| colspan="3" |1000 mg
  +
|-
  +
|[[moxifloxacin]]
  +
|
  +
|
  +
| colspan="5" |400 mg
  +
|-
  +
|[[ethionamide]]
  +
|
  +
|
  +
| colspan="2" |500 mg
  +
| colspan="2" |750 mg
  +
|1000 mg
  +
|-
  +
|[[prothionamide]]
  +
|
  +
|
  +
| colspan="2" |500 mg
  +
| colspan="2" |750 mg
  +
|1000 mg
  +
|-
  +
|[[cycloserine]]
  +
|
  +
|
  +
| colspan="3" |500 mg
  +
| colspan="2" |750 mg
  +
|-
  +
|[[p-aminosalicylic acid]]
  +
|
  +
|
  +
| colspan="4" |4 g bid
  +
|4 g bid to tid
  +
|-
  +
|[[bedaquiline]]
  +
|
  +
|
  +
| colspan="5" |400 mg daily for 2 weeks then 200 mg 3 times per week
  +
|-
  +
|[[clofazimine]]
  +
|
  +
|
  +
| colspan="5" |200-300 mg for 2 months then 100 mg
  +
|-
  +
|[[linezolid]]
  +
|
  +
|
  +
| colspan="5" |600 mg daily
  +
|}
  +
  +
=== Duration ===
  +
{| class="wikitable"
  +
!Syndrome
  +
!Total Duration
  +
!Notes
  +
|-
  +
! colspan="3" |Pulmonary Tuberculosis
  +
|-
  +
|Standard
  +
|6 months
  +
|
  +
|-
  +
|Cavitary disease, with diabetes
  +
|9 months
  +
|
  +
|-
  +
|Elderly >75 years
  +
|9 months
  +
|without pyrazinamide
  +
|-
  +
|High risk of hepatitis
  +
|9 months
  +
|without pyrazinamide
  +
|-
  +
|High risk of recurrence
  +
|9 months
  +
|extensive disease, or baseline cavitary disease with smear or culture positive at 2 months
  +
|-
  +
|Pregnancy
  +
|6-9 months
  +
|with or without pyrazinamide
  +
|-
  +
|[[HIV]] (untreated)
  +
|9 months
  +
|
  +
|-
  +
|Severe liver disease, avoiding RIF
  +
|12-18 months
  +
|without rifampin, isoniazid, and pyrazinamide
  +
|-
  +
|Solid-organ transplant
  +
|9 months
  +
|
  +
|-
  +
|TNF-alpha inhibitors
  +
|9 months
  +
|
  +
|-
  +
! colspan="3" |Extra-Pulmonary Tuberculosis
  +
|-
  +
|Bone and joint
  +
|6-12 months
  +
|high risk of relapse; duration depends on severity of disease
  +
|-
  +
|[[Tuberculous meningitis|CNS TB, meningitis]]
  +
|9-12 months
  +
|with steroids
  +
|-
  +
|CNS TB, tuberculoma or arachnoiditis
  +
|9-12 months
  +
|without steroids unless significant mass effect
  +
|-
  +
|Cutaneous
  +
|6 months
  +
|
  +
|-
  +
|Disseminated disease
  +
|6 months
  +
|
  +
|-
  +
|Disseminated disease, with diabetes
  +
|9 months
  +
|
  +
|-
  +
|Genitourinary
  +
|6 months
  +
|
  +
|-
  +
|[[Tuberculous adenitis|Lymphadenitis]]
  +
|6 months
  +
|surgery not necessary
  +
|-
  +
|Ocular
  +
|6 months
  +
|
  +
|-
  +
|[[Tuberculous pericarditis|Pericarditis]]
  +
|6 months
  +
|with steroids if HIV-negative, without steroids if untreated HIV, unclear use if treated HIV
  +
|-
  +
|[[Pleural tuberculosis|Pleural]]
  +
|6 months
  +
|drainage not necessary
  +
|}
  +
  +
=== Routine Monitoring ===
  +
  +
==== Clinical ====
  +
  +
* Start of treatment: physical examination, weight, visual acuity, colour vision testing
  +
* Follow-up: weight, repeat vision testing monthly while on EMB
  +
* Assess adherence, adverse events, and response to therapy
  +
  +
==== Radiology ====
  +
  +
* Chest x-ray at diagnosis (if not already done as part of diagnostic process), at 2 months, and at end of therapy
  +
  +
==== Laboratory ====
  +
  +
* Start of treatment: CBC, ALT, bilirubin, creatinine, [[HIV]]/[[HBV]]/[[HCV]] serologies, [[HbA1c]]
  +
* Follow-up: monthly CBC, creatinine, ALT, and bilirubin
  +
  +
==== Microbiology ====
  +
  +
* Sputum culture twice monthly (~q2wk) until smear negative
  +
** Repeat susceptibility testing if sputum culture is positive at 3 months
  +
** Sputum induction ''not'' required if unable to produce sputum and smear negative
  +
* Nearing end of therapy, sputum culture 2 months and one month before planned end
  +
** If sputum remains culture positive at 2 months, repeat sputum cultures should be performed monthly until culture conversion is confirmed
  +
  +
===Immune Reconstitution Inflammatory Syndrome (IRIS)===
  +
  +
=== Adverse Drug Reactions ===
  +
  +
==== Drug-Induced Liver Injury (DILI) ====
  +
*Most common complication leading to treatment interruption, with a mortality of 6-12% if drugs are not stopped
  +
*[[Pyrazinamide]], followed by [[isoniazid]], then [[rifampin]], are the most common causes of liver injury[[CiteRef::yee2003in]][[CiteRef::saukkonen2006an]]
  +
*Most patients can have the same TB drugs reintroduced without recurrence of DILI, though recurrence can be delayed
  +
*Procedure
  +
**Hold all medications if ALT >120 (3x ULN) and symptoms, if ALT >200 (5x ULN) even without symptoms, or bili >2x ULN
  +
**If severe disease and patient needs to continue treatment, immediately start two second-line agents (e.g. a fluoroquinolone and an injectable)
  +
**Once AST & ALT are less than twice the upper limit of normal, reintroduce the original drugs every 3 to 5 days, trending enzymes
  +
**Only rechallenge with pyrazinamide if it was a mild case
  +
  +
==== Dermatologic Reactions ====
  +
  +
===== Mild Reactions =====
  +
  +
* Post-dose flushing or itching with or without rash
  +
** Mostly face or scalp, and may involve redness or watering of the eyes
  +
** Usually 2 to 3 hours after drug ingestion
  +
** Caused by [[rifampin]] and [[pyrazinamide]]
  +
** Can use an antihistamine if it is bothersome
  +
* Flushing and/or itching with or without a rash, plus hot flashes, palpitations, headaches, or increased blood pressure
  +
** Immediately after ingestion of certain foods
  +
** Usually resolves within 2 hours
  +
** Caused by [[isoniazid]] plus tyramine-containing foods (cheese, red wine) or certain fish (tuna, skipjack)
  +
** Avoid the causative foods
  +
  +
===== Moderate-to-Severe Reactions =====
  +
  +
* Hives with or without fever
  +
* Caused by [[isoniazid]] < [[rifampin]] < [[pyrazinamide]] < [[ethionamide]] < [[cycloserine]] < [[ethambutol]] < [[Para-aminosalicylic acid|PASA]] < [[streptomycin]]
  +
* In children, viral infections may be confused for hives
  +
  +
===== Management =====
  +
* Discontinue all drugs until the reaction resolves
  +
* Can consider starting TB background regimen with [[levofloxacin]] 15-20 mg daily (max 1 g) plus [[linezolid]] 600 mg
  +
** Substitute [[amikacin]] 15 mg/kg daily if one of the above cannot be given
  +
* Every 4 days, add a new drug back in the following order, with a lower challenge dose on the first day:
  +
** [[Isoniazid]] 50 mg challenge on day 1 followed by 300 mg on day 2
  +
** [[Rifampin]] 75 mg challenge on day 1 followed by 300 mg on day 2
  +
** [[Pyrazinamide]] 250 mg challenge on day 1 followed by 1 g on day 2
  +
** [[Ethionamide]] 125 mg challenge on day 1 followed by 375 mg on day 2
  +
** [[Cycloserine]] 125 mg challenge on day 1 followed by 250 mg on day 2
  +
** [[Ethambutol]] 100 mg on day 1 followed by 500 mg on day 2
  +
** [[Para-aminosalicylic acid|PASA]] 1 g on day 1 followed by 5 g on day 2
  +
** [[Streptomycin]] 125 mg on day 1 followed by 500 mg on day 2
  +
* If the reaction was severe, use 10% of the day 1 dose (e.g. [[isoniazid]] 5 mg)
  +
  +
===Adherence to Treatment===
  +
  +
*Refer to [http://www.letstalktb.org/ Let's Talk TB]
  +
  +
=== Special Populations ===
  +
  +
==== Liver Disease ====
  +
  +
* Most of the first-line medications (except [[ethambutol]]) can cause drug-induced hepatotoxicity and should be avoided
  +
**[[Rifampin]] may be considered in more extensive disease
  +
*In general, a combination of [[fluoroquinolone]] plus [[ethambutol]] plus an injectable such as [[amikacin]] for the first 2 months, followed by [[fluoroquinolone]] and [[ethambutol]] alone to complete 18 months total
  +
  +
==Prevention==
  +
  +
===Vaccination===
  +
  +
*BCG vaccine given at or shortly after birth in many countries
   
  +
===Infection Prevention and Control===
−
=== Immune reconstitution inflammatory syndrome (IRIS) ===
  
   
  +
*All cases of suspected tuberculosis should be placed in airborne isolation until three sputum smears are negative for tuberculosis, unless it is still suspected and no other diagnosis is made
−
=== Drug-induced liver injury (DILI) ===
  
  +
**Sputum samples minimum of 1 hour apart, and at least one early morning sample
−
* Most common complication leading to treatment interruption, with a mortality of 6-12% if drugs are not stopped
  
  +
**Three induced sputa are preferable to one bronchoscopy
−
* [[Pyrazinamide]], followed by [[isoniazid]], then [[rifampin]], are the most common causes of liver injury[[CiteRef::yee2003in]][[CiteRef::saukkonen2006an]]
  
  +
**Can accept a single negative PCR test if patient is low probability
−
* Most patients can have the same TB drugs reintroduced without recurrence of DILI, though recurrence can be delayed
  
  +
**Can accept two negative PCR tests or 1 negative PCR and 2 negative smears if patient is high probability
−
* Procedure
  
  +
*For patients with smear-negative, culture-positive, drug-susceptible respiratory TB:
−
** Hold if ALT &gt;120 and symptoms, if ALT &gt;200 even without symptoms, or bili &gt;2x ULN
  
  +
**Continue airborne precautions until clinical evidence of improvement and a minimum of 2 weeks of effective therapy
−
** Switch to second-line meds
  
  +
**Can be discharged home provided there is clinical improvement, drug-resistant TB is not suspected, and there is no contraindication for home isolation
−
** Reintroduce the original drugs once AST &amp; ALT are &lt;2x ULN
  
  +
*For patient with smear-positive, culture-positive, drug-susceptible respiratory TB:
−
** Only rechallenge with pyrazinamide if it was a mild case
  
  +
**Continue airborne precautions until clinical evidence of improvement and a minimum of 2 weeks of effective therapy
  +
**Can be stopped at 4 weeks, or earlier if there are 3 negative smears
  +
**Can be discharge home as above
  +
*For patients with rifampin- or multidrug-resistant TB:
  +
**Continue airborne precautions as above, but additionally require three negative sputum ''cultures'' to be negative before they are taken out of airborne isolation
   
  +
==Further Reading==
−
=== Adherence to Treatment ===
  
−
* Refer to [http://www.letstalktb.org/ Let's Talk TB]
  
   
  +
*Canadian Tuberculosis Standards, 8th Edition. ''Can J Respiratory Crit Care Sleep Med''. 2022;6:sup1.
−
== Further Reading ==
  
  +
**[https://doi.org/10.1080/24745332.2022.2033062 Chapter 1: Epidemiology of tuberculosis in Canada]
−
* [https://www.canada.ca/en/public-health/services/infectious-diseases/canadian-tuberculosis-standards-7th-edition.html Canadian Canadian Tuberculosis Standards, 7th Edition (2014)]
 
  +
**[https://doi.org/10.1080/24745332.2022.2035540 Chapter 2: Transmission and pathogenesis of tuberculosis]
  +
**[https://doi.org/10.1080/24745332.2022.2035638 Chapter 3: Diagnosis of tuberculosis disease and drug-resistant tuberculosis]
  +
**[https://doi.org/10.1080/24745332.2022.2036503 Chapter 4: Diagnosis of tuberculosis infection]
  +
**[https://doi.org/10.1080/24745332.2022.2036504 Chapter 5: Treatment of tuberculosis disease]
  +
**[https://doi.org/10.1080/24745332.2022.2039498 Chapter 6: Tuberculosis preventive treatment in adults]
  +
**[https://doi.org/10.1080/24745332.2022.2036073 Chapter 7: Extra-pulmonary tuberculosis]
  +
**[https://doi.org/10.1080/24745332.2022.2039499 Chapter 8: Drug-resistant tuberculosis]
  +
**[https://doi.org/10.1080/24745332.2022.2043055 Chapter 9: Pediatric tuberculosis]
  +
**[https://doi.org/10.1080/24745332.2022.2039500 Chapter 10: Treatment of active tuberculosis in special populations]
  +
**[https://doi.org/10.1080/24745332.2022.2037909 Chapter 11: Tuberculosis contact investigation and outbreak management]
  +
**[https://doi.org/10.1080/24745332.2022.2041328 Chapter 12: An introductory guide to tuberculosis care to improve cultural competence for health care workers and public health professionals serving Indigenous Peoples of Canada]
  +
**[https://doi.org/10.1080/24745332.2022.2035544 Chapter 13: Tuberculosis surveillance and tuberculosis infection testing and treatment in migrants]
  +
**[https://doi.org/10.1080/24745332.2022.2043677 Chapter 14: Prevention and control of tuberculosis transmission in healthcare settings]
  +
**[https://doi.org/10.1080/24745332.2022.2035123 Chapter 15: Monitoring tuberculosis program performance]
   
 
{{DISPLAYTITLE:''Mycobacterium tuberculosis''}}
  
{{DISPLAYTITLE:''Mycobacterium tuberculosis''}}
−
[[Category:TB]]
 +
[[Category:Tuberculosis]]
 
[[Category:Mycobacteria]]
  
[[Category:Mycobacteria]]

Latest revision as of 11:12, 13 June 2023

Background

  • Mycobacterium tuberculosis causes tuberculosis
  • Most commonly pulmonary TB but extrapulmonary tuberculosis is possible (including adenitis, gastrointestinal TB, pericarditis, meningitis)
  • Standard treatment for susceptible TB is RIPE x2mo then RI x4mo

Microbiology

  • Fastidious, aerobic acid-fast bacillus
  • Cell wall has high lipid content
  • Generation time is very long (15 to 20 hours)
  • M. tuberculosis is a complex that comprises seven species:
    • M. tuberculosis sensu stricto: most common causative organism worldwide
    • M. africanum: 50% of cases in West africa
    • M. canetti: rare cause in Eastern African
    • M. bovis: disease in cattle but can infect humans
    • M. caprae: disease in cattle
    • M. microti: disease in rodents
    • M. pinnipdeii: disease in seals, with rare human infection

Epidemiology

  • Typically spread via airborne route
    • Droplets are expelled during coughing, sneezing, or talking, and are suspended in the air
    • They can remain for up to 30 minutes
    • Killed by ultraviolet light
    • Not transmitted via fomites
  • About a third of the world is infected, mostly as latent tuberculosis
    • This progresses to active tuberculosis at about 3 or 4% in the first year and 5% over the rest of their life
  • Reinfection accounts for ~40% of active tuberculosis in endemic countries
  • Highest rates in sub-Saharan Africa and south/southeast Asia

Risk Factors

  • Source factors, such as sputum smear positivity, cough, cavitations
  • Exposure duration, closeness of contact
  • Factors in the exposed person, such as immune compromise, HIV status

Clinical Manifestations

Classification

  • Primary vs. reactivation vs. reinfection
  • Latent vs. active

Primary Tuberculosis

  • Primary tuberculosis is usually asymptomatic
  • Possible presentations include mild URTI with cough and/or fever
  • May be seen on CXR as infiltrate in mid-lung zones with hilar adenopathy
  • Ghon complex, especially in children
  • May progress in children and the immunocompromised patients
  • Immunological phenomena
    • Erythema nodosum
    • Phlyctenular conjunctivitis
    • Erythema induratum

Pulmonary Tuberculosis

Extra-Pulmonary Tuberculosis

Latent Tuberculosis

Other

Investigations

  • Radiography: chest x-ray with or without CT chest
    • Primary TB: consolidation, lymphadenopathy, pleural effusion, Ghon complex
    • Reactivation TB: patchy upper-lobe consolidation, cavitation, fibrosis, pleural disease
    • Miliary TB: uniform 1-3 mm diameter diffuse nodules

Diagnosis

  • Latent tuberculosis testing
    • Tuberculin skin test (TST)
    • Interferon-gamma release assay (IGRA)
  • Serology or immunologic testing
    • Urine lipoarabinomannan antigen
  • Microbiology
    • Samples can include routine or induced sputum (x3 q8h including 1 early AM) or bronchoscopy, or tissue sample
    • Spontaneous sputum should include at least one morning sputum, ideally, but can be done all in a row at least one hour apart if needed
    • Acid-fast bacillus culture of sputum x3 is about 70% sensitive, and PCR (ANTB) x1 is about 75% sensitive
  • Molecular testing
    • PCR, including GeneXpert

Management

  • Requires at least 2 effective drugs at all times, including at least 3 effective drugs during intensive phase
    • Consider rapid rifampin resistance testing (PCR) in all patients
  • Most patients are started on RIPE
    • In cases of increased risk for MDR-TB, still use RIPE while awaiting rapid rifampin testing
    • Typical duration is intensive therapy for 2 months (with at least 3 drugs), then narrowed to at least 2 drugs for the remainder of treatment
    • Rifampin is the most effective agent, and any regimen that excludes rifampin must be extended to 12-18 months
  • See also:

Antibiotics

Drug Dose Side effects
First-Line Medications
Rifampin 10 mg/kg daily, no max Drug interactions, rash, hepatitis, flu-like illness, neutropenia, thrombocytopenia
Isoniazid 5 mg/kg daily, max 300 mg daily, with pyridoxine 25 mg po daily Rash, hepatitis, neuropathy, CNS toxicity, anemia
Pyrazinamide 25 mg/kg daily, max 2 g daily Hepatitis, rash, arthralgia, gout
Ethambutol 15 mg/kg daily, max 1.6 g daily Optic/retrobulbar neuritis, rash
Second-Line Medications
Streptomycin 15 mg/kg daily, max 1 g Auditory and vestibular toxicity, renal toxocity, avoid in pregnancy
Amikacin, kanamycin, or capreomycin 15 mg/kg daily, man 1 g
Ethionamide 250 mg BID to TID, max 1 g GI disturbance, hepatotoxicity, endocrine effects, neurotoxicity, avoid in pregnancy
Para-amino salicylic acid 4 g BID or TID, max 10 g GI disturbance, hepatic dysfunction, hypothyroidism, avoid in aspirin allergy
Cycloserine 250 mg BID to TID, max 1 g Avoid in epilepsy, psychiatric illness, and alcoholism
Levofloxacin 500 to 1000 mg po daily GI disturbance, headache, anxiety, tremor, long QT, avoid in pregnancy and children
Moxifloxacin 400 to 600 mg daily
Rifabutin 300 mg daily Hepatotoxicity, uveitis, thrombocytopenia, neutropenia, drug interactions
Clofazimine 100 to 300 mg daily Skin discolouration, conjunctiva, cornea, body fluid discolouration, GI intolerance, photosensitivity
Third-Line Medications
Linezolid 600 mg po daily
Bedaquiline 400 mg po daily for 2 weeks followed by 200 mg thrice weekly Arthralgias, dizziness, headache, hyperuriemia, insomnia, myalgia, nausea, prolonged ECG QT interval, pruritus, and vomiting
Pretomanid
Delamanid
Adjunctive Therapies
Corticosteroids for patients with tuberculous meningitis or tuberculous pericarditis Prednisone 40 to 80 mg po daily for 6 to 12 weeks

Doses by Weight

Drug Dose Tabs Weight (kg)
30-35 36-45 46-55 56-70 >70
First-Line Medications
rifampin 10 mg/kg 150 & 300 mg 300 mg 450 mg 600 mg
isoniazid 5 mg/kg 100 & 300 mg 150 mg 200 mg 300 mg
pyrazinamide 25 mg/kg 500 mg 750 mg 1000 mg 1250 mg 1500 mg 1750-2000 mg
ethambutol 15 mg/kg 100 & 400 mg 600 mg 800 mg 1000 mg 1200 mg
Alternative Medications
rifabutin 300 mg
levofloxacin 750 mg 1000 mg
moxifloxacin 400 mg
ethionamide 500 mg 750 mg 1000 mg
prothionamide 500 mg 750 mg 1000 mg
cycloserine 500 mg 750 mg
p-aminosalicylic acid 4 g bid 4 g bid to tid
bedaquiline 400 mg daily for 2 weeks then 200 mg 3 times per week
clofazimine 200-300 mg for 2 months then 100 mg
linezolid 600 mg daily

Duration

Syndrome Total Duration Notes
Pulmonary Tuberculosis
Standard 6 months
Cavitary disease, with diabetes 9 months
Elderly >75 years 9 months without pyrazinamide
High risk of hepatitis 9 months without pyrazinamide
High risk of recurrence 9 months extensive disease, or baseline cavitary disease with smear or culture positive at 2 months
Pregnancy 6-9 months with or without pyrazinamide
HIV (untreated) 9 months
Severe liver disease, avoiding RIF 12-18 months without rifampin, isoniazid, and pyrazinamide
Solid-organ transplant 9 months
TNF-alpha inhibitors 9 months
Extra-Pulmonary Tuberculosis
Bone and joint 6-12 months high risk of relapse; duration depends on severity of disease
CNS TB, meningitis 9-12 months with steroids
CNS TB, tuberculoma or arachnoiditis 9-12 months without steroids unless significant mass effect
Cutaneous 6 months
Disseminated disease 6 months
Disseminated disease, with diabetes 9 months
Genitourinary 6 months
Lymphadenitis 6 months surgery not necessary
Ocular 6 months
Pericarditis 6 months with steroids if HIV-negative, without steroids if untreated HIV, unclear use if treated HIV
Pleural 6 months drainage not necessary

Routine Monitoring

Clinical

  • Start of treatment: physical examination, weight, visual acuity, colour vision testing
  • Follow-up: weight, repeat vision testing monthly while on EMB
  • Assess adherence, adverse events, and response to therapy

Radiology

  • Chest x-ray at diagnosis (if not already done as part of diagnostic process), at 2 months, and at end of therapy

Laboratory

  • Start of treatment: CBC, ALT, bilirubin, creatinine, HIV/HBV/HCV serologies, HbA1c
  • Follow-up: monthly CBC, creatinine, ALT, and bilirubin

Microbiology

  • Sputum culture twice monthly (~q2wk) until smear negative
    • Repeat susceptibility testing if sputum culture is positive at 3 months
    • Sputum induction not required if unable to produce sputum and smear negative
  • Nearing end of therapy, sputum culture 2 months and one month before planned end
    • If sputum remains culture positive at 2 months, repeat sputum cultures should be performed monthly until culture conversion is confirmed

Immune Reconstitution Inflammatory Syndrome (IRIS)

Adverse Drug Reactions

Drug-Induced Liver Injury (DILI)

  • Most common complication leading to treatment interruption, with a mortality of 6-12% if drugs are not stopped
  • Pyrazinamide, followed by isoniazid, then rifampin, are the most common causes of liver injury12
  • Most patients can have the same TB drugs reintroduced without recurrence of DILI, though recurrence can be delayed
  • Procedure
    • Hold all medications if ALT >120 (3x ULN) and symptoms, if ALT >200 (5x ULN) even without symptoms, or bili >2x ULN
    • If severe disease and patient needs to continue treatment, immediately start two second-line agents (e.g. a fluoroquinolone and an injectable)
    • Once AST & ALT are less than twice the upper limit of normal, reintroduce the original drugs every 3 to 5 days, trending enzymes
    • Only rechallenge with pyrazinamide if it was a mild case

Dermatologic Reactions

Mild Reactions
  • Post-dose flushing or itching with or without rash
    • Mostly face or scalp, and may involve redness or watering of the eyes
    • Usually 2 to 3 hours after drug ingestion
    • Caused by rifampin and pyrazinamide
    • Can use an antihistamine if it is bothersome
  • Flushing and/or itching with or without a rash, plus hot flashes, palpitations, headaches, or increased blood pressure
    • Immediately after ingestion of certain foods
    • Usually resolves within 2 hours
    • Caused by isoniazid plus tyramine-containing foods (cheese, red wine) or certain fish (tuna, skipjack)
    • Avoid the causative foods
Moderate-to-Severe Reactions
Management
  • Discontinue all drugs until the reaction resolves
  • Can consider starting TB background regimen with levofloxacin 15-20 mg daily (max 1 g) plus linezolid 600 mg
    • Substitute amikacin 15 mg/kg daily if one of the above cannot be given
  • Every 4 days, add a new drug back in the following order, with a lower challenge dose on the first day:
    • Isoniazid 50 mg challenge on day 1 followed by 300 mg on day 2
    • Rifampin 75 mg challenge on day 1 followed by 300 mg on day 2
    • Pyrazinamide 250 mg challenge on day 1 followed by 1 g on day 2
    • Ethionamide 125 mg challenge on day 1 followed by 375 mg on day 2
    • Cycloserine 125 mg challenge on day 1 followed by 250 mg on day 2
    • Ethambutol 100 mg on day 1 followed by 500 mg on day 2
    • PASA 1 g on day 1 followed by 5 g on day 2
    • Streptomycin 125 mg on day 1 followed by 500 mg on day 2
  • If the reaction was severe, use 10% of the day 1 dose (e.g. isoniazid 5 mg)

Adherence to Treatment

Special Populations

Liver Disease

Prevention

Vaccination

  • BCG vaccine given at or shortly after birth in many countries

Infection Prevention and Control

  • All cases of suspected tuberculosis should be placed in airborne isolation until three sputum smears are negative for tuberculosis, unless it is still suspected and no other diagnosis is made
    • Sputum samples minimum of 1 hour apart, and at least one early morning sample
    • Three induced sputa are preferable to one bronchoscopy
    • Can accept a single negative PCR test if patient is low probability
    • Can accept two negative PCR tests or 1 negative PCR and 2 negative smears if patient is high probability
  • For patients with smear-negative, culture-positive, drug-susceptible respiratory TB:
    • Continue airborne precautions until clinical evidence of improvement and a minimum of 2 weeks of effective therapy
    • Can be discharged home provided there is clinical improvement, drug-resistant TB is not suspected, and there is no contraindication for home isolation
  • For patient with smear-positive, culture-positive, drug-susceptible respiratory TB:
    • Continue airborne precautions until clinical evidence of improvement and a minimum of 2 weeks of effective therapy
    • Can be stopped at 4 weeks, or earlier if there are 3 negative smears
    • Can be discharge home as above
  • For patients with rifampin- or multidrug-resistant TB:
    • Continue airborne precautions as above, but additionally require three negative sputum cultures to be negative before they are taken out of airborne isolation

Further Reading

References

  1. ^  Daphne Yee, Chantal Valiquette, Marthe Pelletier, Isabelle Parisien, Isabelle Rocher, Dick Menzies. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 2003;167(11):1472-1477. doi:10.1164/rccm.200206-626oc.
  2. ^  Jussi J. Saukkonen, David L. Cohn, Robert M. Jasmer, Steven Schenker, John A. Jereb, Charles M. Nolan, Charles A. Peloquin, Fred M. Gordin, David Nunes, Dorothy B. Strader, John Bernardo, Raman Venkataramanan, Timothy R. Sterling. An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy. American Journal of Respiratory and Critical Care Medicine. 2006;174(8):935-952. doi:10.1164/rccm.200510-1666st.

Retrieved from "https://idwiki.org/index.php?title=Mycobacterium_tuberculosis&oldid=10002"
Powered by MediaWiki
Powered by Semantic MediaWiki